Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with asbestos.
Pembrolizumab Approved With Chemotherapy for Malignant Pleural Mesothelioma
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy.
Keytruda Plus Chemotherapy Approved for Malignant Pleural Mesothelioma
The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.
FDA Approves Frontline Pembrolizumab/Chemotherapy in Advanced Mesothelioma
Pembrolizumab plus chemotherapy is now an approved frontline treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Merck Gets First FDA Approval of Keytruda in Malignant Pleural Mesothelioma
Merck & Co. has won its first U.S. approval for use of its blockbuster cancer drug Keytruda in patients with malignant pleural mesothelioma, a rare cancer that grows in the membrane that lines the walls of the chest and lungs.
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Merck’s Keytruda label expanded in the U.S. for mesothelioma
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination therapy for mesothelioma,
The Brighterside of News on MSN2d
Breakthrough cancer treatment destroys advanced-stage tumors in under 6 days
Researchers from Rice University and Baylor College of Medicine have demonstrated a groundbreaking treatment that eradicates ...
$39M Jury Verdict Awarded in Novel Mesothelioma Case
Plaintiffs' lead attorney Mark Linder emphasized this is the first mesothelioma lawsuit that proceeded from this type of ...
Acsh.org2d
On the Toxic Tort Docket
Recent surprise decisions have upended plaintiffs’ expectations on the toxic tort front. In Delaware, the top court is ...
FiercePharma5d
J&J talc appeal upends $260M award to Oregon woman with mesothelioma
Three months after a jury awarded $260 million to an Oregon woman who claimed her use of Johnson’s Baby Powder caused her to ...
mskcc.org19d
How MSK Is Teaching CAR T Cells to Attack Solid Tumors
To treat mesothelioma with CAR T Cells, that means injecting the cells directly into the pleural cavity — the area outside ...
J&J gets $260 million talc verdict overturned in Oregon, new trial ordered
A state judge in Oregon has overturned a jury's $260 million verdict against Johnson & Johnson in a lawsuit brought by a ...
devdiscourse5d
Judge Overturns $260 Million Verdict Against Johnson & Johnson in Talc Mesothelioma Case
A state judge in Oregon has overturned a $260 million verdict against Johnson & Johnson in a mesothelioma lawsuit. The judge ...
Best Mesothelioma Lawyers Dallas, TX Of 2024
For decades, shipyard workers at Texas ports, Texas oil refinery workers and U.S. soldiers at Dallas-area bases inhaled ...